2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Perceptive Advisors Llc | Director | 5,402,964 | Dec 29, 2023 |
| Perceptive Life Sciences Master Fund Ltd | Director | 5,402,964 | Dec 29, 2023 |
| Wong Roderick | 10% Owner | 1,535,131 | Sep 22, 2020 |
| Rtw Investments, Lp | 10% Owner | 1,535,131 | Sep 22, 2020 |
| Kawas Leen | — | 231,000 | Feb 22, 2021 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Mar 5, 2026 | Litton Mark James | CEO | Sell | 46.3 | -5,156 | -7.93% | ✗ | $27.7K |
| Mar 3, 2026 | Mar 5, 2026 | Renninger Robert | CFO | Sell | 47.5 | -906 | -5.41% | ✗ | $4.9K |
| Mar 3, 2026 | Mar 5, 2026 | Worthington Mark | GENERAL COUNSEL and CCO | Sell | 47.5 | -1,328 | -6.74% | ✗ | $7.1K |
| Mar 3, 2026 | Mar 5, 2026 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 47.5 | -1,359 | -5.12% | ✗ | $7.3K |
| Mar 3, 2026 | Mar 5, 2026 | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 47.5 | -1,720 | -9.77% | ✗ | $9.2K |
| Dec 31, 2025 | Jan 5, 2026 | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 46.3 | -1,644 | -13.89% | ✗ | $11.3K |
| Dec 31, 2025 | Jan 5, 2026 | Litton Mark James | CEO | Sell | 46.3 | -2,586 | -5.70% | ✗ | $17.8K |
| Nov 18, 2025 | Jan 5, 2026 | Renninger Robert | CFO | Sell | 82.5 | +703 | 2.92% | ✗ | $2K |
| Nov 18, 2025 | Jan 5, 2026 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 60.0 | +124 | 0.32% | ✗ | $6K |
| Dec 31, 2025 | Jan 5, 2026 | Worthington Mark | General Counsel and CCO | Sell | 47.5 | -876 | -5.90% | ✗ | $6K |
| Dec 24, 2025 | Dec 29, 2025 | Renninger Robert | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 24, 2025 | Dec 29, 2025 | Litton Mark James | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 24, 2025 | Dec 29, 2025 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 24, 2025 | Dec 29, 2025 | San Martin Javier | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 24, 2025 | Dec 29, 2025 | Worthington Mark | General Counsel and CCO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 23, 2025 | Dec 23, 2025 | PERCEPTIVE ADVISORS LLC | Director | Neutral | 90.0 | +1,319,026 | 244.13% | ✗ | - |
| May 19, 2025 | Jul 2, 2025 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 60.0 | +1,474 | 0.48% | ✗ | $2.5K |
| Jun 30, 2025 | Jul 2, 2025 | Litton Mark James | CEO | Sell | 47.5 | -25,123 | -6.78% | ✗ | $7.4K |
| Jun 30, 2025 | Jul 2, 2025 | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 47.5 | -10,842 | -13.14% | ✗ | $3.2K |
| Jun 30, 2025 | Jul 2, 2025 | Worthington Mark | General Counsel and CCO | Sell | 47.5 | -8,526 | -7.08% | ✗ | $2.5K |
| May 19, 2025 | Jul 2, 2025 | Renninger Robert | SVP, Finance and Accounting | Sell | 82.5 | +7,103 | 3.52% | ✗ | $850.3 |
| May 30, 2025 | Jun 3, 2025 | FLUKE JOHN M JR | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | Panzara Michael A. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | Romano Kelly A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | EDELMAN JOSEPH | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | JOHNSON JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | Kosacz Barbara | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 30, 2025 | Jun 3, 2025 | PICKERING GRANT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 12, 2025 | Renninger Robert | SVP, Finance and Accounting | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | Renninger Robert | SVP, Finance and Accounting | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | Litton Mark James | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | San Martin Javier | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | Worthington Mark | General Counsel and CCO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 31, 2024 | Jan 3, 2025 | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 47.5 | -10,826 | -23.20% | ✗ | $6.1K |
| Dec 31, 2024 | Jan 3, 2025 | Litton Mark James | CEO | Sell | 46.3 | -25,107 | -8.74% | ✗ | $14.1K |
| Nov 18, 2024 | Jan 3, 2025 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 67.5 | +1,410 | 0.61% | ✗ | $4.8K |
| Nov 18, 2024 | Jan 3, 2025 | Renninger Robert | VP of Finance | Sell | 60.0 | +770 | 0.46% | ✗ | $1.6K |
| Nov 18, 2024 | Jan 3, 2025 | Worthington Mark | General Counsel and CCO | Sell | 47.5 | -4,859 | -3.37% | ✗ | $4.8K |
| Oct 3, 2024 | Oct 3, 2024 | Litton Mark James | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 1, 2024 | Oct 3, 2024 | Renninger Robert | VP of Finance | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 1, 2024 | Oct 3, 2024 | San Martin Javier | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 1, 2024 | Oct 3, 2024 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 1, 2024 | Oct 3, 2024 | Worthington Mark | General Counsel and CCO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 3, 2024 | Oct 3, 2024 | Litton Mark James | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 3, 2024 | Renninger Robert | VP of Finance | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 20, 2024 | Sep 5, 2024 | Gengos Andrew | CFO | Sell | 90.0 | +13,728 | 16.38% | ✗ | $720 |
| Sep 3, 2024 | Sep 5, 2024 | Lenington Rachel | COO | Sell | 90.0 | +7,475 | 55.80% | ✗ | $1.4K |
| May 20, 2024 | Sep 5, 2024 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 90.0 | +12,428 | 15.49% | ✗ | $1.4K |
| May 20, 2024 | Sep 5, 2024 | Worthington Mark | GENERAL COUNSEL | Sell | 90.0 | +17,475 | 50.72% | ✗ | $1.4K |
| Sep 3, 2024 | Sep 5, 2024 | Litton Mark James | CEO | Sell | 85.0 | +14,968 | 9.12% | ✗ | $2.8K |
| Jun 21, 2024 | Jun 25, 2024 | Romano Kelly A | Director | Buy | 95.0 | +42,400 | 110.66% | ✗ | $100.1K |
| May 24, 2024 | May 24, 2024 | Romano Kelly A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | EDELMAN JOSEPH | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | JOHNSON JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | Kosacz Barbara | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | Panzara Michael A. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | PICKERING GRANT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 24, 2024 | May 24, 2024 | FLUKE JOHN M JR | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 15, 2024 | Apr 16, 2024 | San Martin Javier | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 16, 2024 | San Martin Javier | CHIEF MEDICAL OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 15, 2024 | Feb 16, 2024 | Litton Mark James | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 14, 2024 | Feb 16, 2024 | Worthington Mark | GENERAL COUNSEL | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 14, 2024 | Feb 16, 2024 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 14, 2024 | Feb 16, 2024 | Gengos Andrew | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 14, 2024 | Feb 16, 2024 | Lenington Rachel | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 4, 2024 | Feb 16, 2024 | Lenington Rachel | COO | Sell | 90.0 | +7,588 | 130.67% | ✗ | $7K |
| Jan 4, 2024 | Feb 16, 2024 | Litton Mark James | CEO | Sell | 91.3 | +15,180 | 10.19% | ✗ | $14K |
| May 18, 2023 | Feb 16, 2024 | Worthington Mark | GENERAL COUNSEL | Sell | 90.0 | +15,355 | 80.41% | ✗ | $7K |
| Jan 4, 2024 | Feb 16, 2024 | Gengos Andrew | CFO | Sell | 82.5 | +3,792 | 4.74% | ✗ | $3.5K |
| May 18, 2023 | Feb 16, 2024 | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 90.0 | +11,794 | 17.23% | ✗ | $7K |
| Jan 4, 2024 | Jan 8, 2024 | MOEBIUS HANS | Chief Medical Officer | Neutral | 90.0 | +10,000 | 12.27% | ✗ | - |
| Jan 4, 2023 | Jan 8, 2024 | Gengos Andrew | See Below | Sell | 82.5 | +3,792 | 4.74% | ✗ | $3.5K |
| Jan 4, 2024 | Jan 8, 2024 | Litton Mark James | CEO | Sell | 91.3 | +15,180 | 10.19% | ✗ | $14K |
| May 18, 2023 | Jan 8, 2024 | Worthington Mark | General Counsel | Sell | 90.0 | +15,355 | 80.41% | ✗ | $7K |
| May 18, 2023 | Jan 8, 2024 | CHURCH KEVIN | Chief Scientific Officer | Sell | 82.5 | +11,794 | 4.02% | ✗ | $7K |
| Jan 4, 2024 | Jan 8, 2024 | Lenington Rachel | COO | Sell | 90.0 | +7,588 | 130.67% | ✗ | $7K |
| Dec 27, 2023 | Dec 29, 2023 | PERCEPTIVE ADVISORS LLC | Director | Buy | 100.0 | +605,686 | 12.63% | ✗ | $1.5M |
| Jun 7, 2023 | Jun 9, 2023 | Gengos Andrew | See Below | Buy | 95.0 | +15,000 | 23.07% | ✗ | $51.4K |
| Jun 2, 2023 | Jun 6, 2023 | Gengos Andrew | See Below | Buy | 95.0 | +65,012 | 100.00% | ✗ | $191.6K |
| May 18, 2023 | Jun 6, 2023 | MOEBIUS HANS | Chief Medical Officer | Neutral | 90.0 | +7,764 | 11.79% | ✗ | - |
| May 19, 2023 | May 22, 2023 | Romano Kelly A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | JOHNSON JAMES A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | Kosacz Barbara | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | EDELMAN JOSEPH | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | Panzara Michael A. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | FLUKE JOHN M JR | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 19, 2023 | May 22, 2023 | PICKERING GRANT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 18, 2023 | May 22, 2023 | Gengos Andrew | See Below | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 22, 2023 | Gengos Andrew | See Below | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 29, 2023 | Mar 31, 2023 | PICKERING GRANT | Director | Buy | 95.0 | +25,000 | 3192.85% | ✗ | $60.4K |
| Mar 29, 2023 | Mar 30, 2023 | JOHNSON JAMES A | Director | Buy | 91.3 | +5,000 | 100.00% | ✗ | $12K |
| Mar 24, 2023 | Mar 27, 2023 | CHURCH KEVIN | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 18, 2022 | Jan 31, 2023 | Litton Mark James | CEO | Neutral | 60.0 | +662 | 0.45% | ✗ | - |
| Jan 19, 2023 | Jan 23, 2023 | Worthington Mark | General Counsel | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 19, 2023 | Jan 23, 2023 | MOEBIUS HANS | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 19, 2023 | Jan 23, 2023 | MILESON GLENNA | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 19, 2023 | Jan 23, 2023 | Lenington Rachel | COO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 18, 2022 | Jan 23, 2023 | CHURCH KEVIN | Executive VP, Research | Neutral | 77.5 | +657 | 1.07% | ✗ | - |
| Nov 18, 2022 | Dec 30, 2022 | MILESON GLENNA | CFO | Buy | 95.0 | +50,763 | 46.50% | ✗ | $142.3K |